ALK

10:43
Updates in ALK+ NSCLC
Ross Camidge
3:04
Management of frontline ALK+ NSCLC: brigatinib vs. alectinib
Riyaz Shah
2:35
Brain metastases in ALK+ NSCLC
Natasha Leighl
0:51
UK excels at molecular testing for lung cancer
Riyaz Shah
4:38
Lung cancer molecular testing in the UK
Neal Navani
4:16
Lung cancer: actionable targets
Samreen Ahmed
2:21
Current treatment landscape for ALK-positive NSCLC
Marina Garassino
3:43
Biomarkers in NSCLC: a pathologist’s insight into PD-L1 and TMB
Alex Haragan
0:58
Challenges and treatment of CNS metastases in NSCLC
Sanjay Popat
3:16
Impact of new TKIs on NSCLC treatment planning
Nicolas Girard
1:23
Optimizing treatment of ALK+ NSCLC: clinical realities
Silvia Novello
1:34
Therapy sequencing in the current NSCLC treatment landscape
Nicolas Girard
1:34
Personalized therapy in thoracic malignancies
Dean Fennell
4:43
A new role for pharmacists in the personalized treatment of cancer patients?
Christine Walko
2:42
Off-label medication use in lung cancer
Federico Cappuzzo
1:26
Assessment and diagnostic workup for NSCLC in 2018
Nathan Penell
VJOncology VJOncology is intended for Healthcare Professionals only

By choosing to continue, you are confirming that you are a healthcare professional

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter

Subscribe now
The content of VJOncology is intended for healthcare professionals